cancer
Conditions
Interventions
A:FMT+immunotherapy
Sponsors
The Tenth People's Hospital, Medical School of Tongji University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: a. Aged >= 18 years; b. Gender is not limited; c. Patients with malignant tumor who had received PD-1 / L1 inhibitor, CTLA-4 inhibitor or cart therapy and were evaluated as SD or PD; d. The expected survival time is more than 3 months; e. ECOG (Eastern Cooperative Oncology Group, ECoG) score was 0-2; f. Ability to sign informed consent.
Exclusion criteria
Exclusion criteria: a. Patients with autoimmune diseases or extremely low immunity, or other diseases requiring systemic immunosuppressive drugs or hormone therapy; b. HIV positive or active hepatitis B or C infection; c. Patients with dysphagia or digestive tract obstruction; d. Pregnant or lactating women; e. Patients who received flora transplantation within half a year.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Gut microbiome;Immune status;Side effects of FMT; | — |
Secondary
| Measure | Time frame |
|---|---|
| Tumor efficacy related indicators;Immune related side effects; | — |
Countries
China
Contacts
Public ContactQin Huanlong
The Tenth People's Hospital, Medical School of Tongji University
Outcome results
None listed